<DOC>
	<DOCNO>NCT02286362</DOCNO>
	<brief_summary>This non-interventional prospective study ass safety Herceptin SC ( subcutaneous administration ) use routine clinical practice . Patients HER2-positive early breast cancer , naive non-naive HER2+ treatment treat neoadjuvant adjuvant setting schedule initiate treatment Herceptin SC routine clinical practice use eligible participate . The total study duration anticipate 38 month .</brief_summary>
	<brief_title>An Observational Study Safety Herceptin Given Subcutaneously Patients With Early HER2-positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Aged &gt; /= 18 year Patients HER2positive early breast cancer accord national guideline eligible neoadjuvant adjuvant HER2+ treatment Patients investigator decide start treatment Herceptin SC Trastuzumab treatment naive nonnaive ( previously intravenous treatment ) Informed consent Patients previously treat Herceptin SC treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>